ALVR AlloVir
- 0.816
- +0.035+4.43%
- 0.793
- -0.023-2.84%
AlloVir News
Maintaining a Hold: AlloVir's Strategic Uncertainty and Financial Outlook
ALLOVIR SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $25,000 investing in AlloVir stock or options between March 22, 2022 and December 21, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson
AlloVir Faces Delisting Risk, Considers Reverse Split to Comply
AlloVir(ALVR.US) Officer Sells US$7,493.92 in Common Stocks
$AlloVir(ALVR.US)$ Officer Hagen Brett R sold 11,150 shares of Common Stocks on Feb 8, 2024 at an average price of $0.6721 for a total value of $7,493.92.Source: Announcement What is statement of chan
Top 4 Health Care Stocks That May Rocket Higher In Q1
The most oversold stocks in the health care presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to i
AlloVir To Cut 95% of Workforce After Discontinuing Trials
By Ben Glickman AlloVir will cut about 95% of its current employee base after scrapping three late-stage clinical trials. The cell-therapy developer said in a regulatory filing Thursday that the lay
On January 1, 2024, AlloVir Board Approved Reduction Its Workforce By Approximately 95% Of Current Employee Base To Reduce Costs And Preserve Capital - Filing
The move follows AlloVir's announcement on December 22, 2023 that it is discontinuing its three global Phase 3 posoleucel studies. This workforce reduction will take place primarily during the first q
AlloVir(ALVR.US) Officer Sells US$20,837.56 in Common Stocks
$AlloVir(ALVR.US)$ Officer Hagen Brett R sold 28,335 shares of Common Stocks on Dec 27, 2023 at an average price of $0.7354 for a total value of $20,837.56.Source: Announcement What is statement of ch
Analysts' Opinions Are Mixed on These Healthcare Stocks: Karuna Therapeutics (KRTX), AlloVir (ALVR) and Top Glove Bhd (OtherTGLVY)
We're Keeping An Eye On AlloVir's (NASDAQ:ALVR) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring reve
AlloVir Downgraded to Equal Weight at Morgan Stanley
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwri
AlloVir Cut to Underperform From Buy by B of A Securities
AlloVir Cut to Underperform From Buy by B of A Securities
B of A Securities Downgrades AlloVir to Underperform, Lowers Price Target to $1
B of A Securities analyst Jason Zemansky downgrades AlloVir (NASDAQ:ALVR) from Buy to Underperform and lowers the price target from $17 to $1.
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), AlloVir (ALVR) and Bristol-Myers Squibb (BMY)
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersKaruna Therapeutics (NASDAQ:KRTX) shares increased by 47.4% to $317.1 during Monday's pre-market session. The company's market cap stands at $11.9 billion. Universe Pharmaceuticals (NASDAQ:UPC)
U.S. Shares Mixed at Close of Trade; Dow Jones Industrial Average Down 0.05%
Sector Update: Health Care Stocks Gain in Late Afternoon
Health care stocks rose late Friday afternoon with the NYSE Health Care Index adding 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.4%. The iShares Biotechnology ETF (IBB) rose 2.2%. In c
Sector Update: Health Care
Health care stocks were rising late Friday afternoon, with the NYSE Health Care Index adding 0.4% and the Health Care Select Sector SPDR Fund (XLV) up 0.4%. The iShares Biotechnology ETF (IBB) rose 2.
Hold Rating on AlloVir Following Posoleucel Program Discontinuation and Strategic Shift
Analysis
Price Target
No Data
